腫瘍病理鑑別診断アトラス 骨腫瘍　第2版

出版社： 文光堂
著者：
発行日： 2021-03-16
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622557
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2021-03-16 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

商品紹介

腫瘍病理鑑別診断アトラスシリーズ「骨腫瘍」，待望の第2版．近年，分子生物学的解析により疾患概念が変化し，さらにはWHO分類第5版（2020）が発行されるなど，骨腫瘍の病理診断の考え方は日々更新されている．そうした状況を踏まえ，骨腫瘍の中でも高頻度のものを中心に，最新の知見を盛り込んで診断のポイントとなり得る組織像を供覧し，解説．そして骨腫瘍病理診断のスタンダードを示すとともに，鑑別診断，画像診断や治療法・評価など，病理診断に欠かせない知識も盛り込んだ．病理医はもちろん，骨腫瘍の診断･治療に携わるすべての医師必携の書．

目次

  • 第1部　検鏡前の確認事項
    　I．骨腫瘍のWHO分類第5版の概要
    　　1．疾患単位の追加
    　　2．疾患単位の削除
    　　3．gradeの変更
    　　4．その他の変更
    　II．骨腫瘍の頻度，年齢，発生部位
    　　1．骨腫瘍の発生頻度
    　　2．骨腫瘍の発生年齢
    　　3．骨腫瘍の発生部位
    　III．病理標本の取扱い方
    　　1．術中迅速診断
    　　2．生検検体
    　　3．手術検体

    第2部　組織型と診断の実際
    　I．軟骨形成性腫瘍
    　　1．良性軟骨形成性腫瘍
    　　（1）骨軟骨腫，内軟骨腫，骨膜性軟骨腫
    　　（2）軟骨芽細胞腫と軟骨粘液線維腫
    　　2．中心性・末梢性・骨膜性軟骨肉腫
    　　3．特殊型軟骨肉腫
    　II．骨形成性腫瘍
    　　1．良性・中間群骨形成性腫瘍
    　　2．通常型骨肉腫
    　　3．特殊型骨肉腫
    　　4．表在性骨肉腫
    　III．線維性および線維組織球性腫瘍
    　　1．骨類腱線維腫と非骨化性線維腫
    　IV．破骨細胞型巨細胞に富む腫瘍
    　　1．指趾骨巨細胞性病変と巨細胞修復性肉芽腫
    　　2．動脈瘤様骨囊腫
    　　3．骨巨細胞腫
    　V．脊索性腫瘍
    　　1．良性脊索細胞腫および脊索腫
    　VI．血管性腫瘍
    　　1．血管腫および類上皮血管腫
    　　2．類上皮血管内皮腫および血管肉腫
    　VII．その他の腫瘍
    　　1．単純性骨囊腫
    　　2．線維性骨異形成
    　　3．Langerhans細胞組織球症
    　　4．骨線維性異形成
    　　5．アダマンチノーマ
    　　6．Ewing肉腫とEwing様肉腫
    　　7．骨未分化多形肉腫と骨平滑筋肉腫
    　VIII．関節腫瘍
    　　1．腱滑膜巨細胞腫
    　　2．滑膜軟骨腫症
    　　3．滑膜脂肪腫

    第3部　鑑別ポイント
    　I．骨肉腫との鑑別を要する骨形成性腫瘍
    　　1．骨肉腫の亜型と特徴
    　　2．髄内骨肉腫と表在性骨肉腫の関係
    　　3．組織所見からみた骨肉腫の鑑別診断
    　II．軟骨肉腫との鑑別を要する軟骨形成性腫瘍
    　　1．軟骨芽細胞型骨肉腫
    　　2．内軟骨腫
    　　3．軟骨芽細胞腫
    　　4．軟骨粘液線維腫
    　　5．線維軟骨性異形成
    　　6．線維軟骨性間葉腫
    　　7．滑膜軟骨腫症
    　　8．ピロリン酸カルシウム結晶沈着症
    　III．巨細胞の出現する腫瘍の鑑別
    　　1．臨床的事項
    　　2．組織学的診断時の注意事項
    　　3．多核巨細胞の出現する骨疾患の組織学的特徴　
    　IV．骨小円形細胞腫瘍の鑑別
    　　1．Ewing肉腫といわゆるEwing様肉腫
    　　2．小細胞型骨肉腫とEwing肉腫
    　　3．骨リンパ腫
    　　4．形質細胞腫瘍
    　　5．間葉性軟骨肉腫と骨肉腫
    　　6．癌腫の転移
    　　7．その他の鑑別
    　V．転移性骨腫瘍と上皮様骨腫瘍の鑑別
    　　1．定義・概念
    　　2．鑑別の要点
    　　3．上皮様骨腫瘍の鑑別診断の実際

    第4部　臨床との連携
    　I．骨腫瘍の手術療法
    　　1．骨腫瘍に対する標準的手術療法
    　　2．手術後の再建法
    　II．骨腫瘍の画像診断
    　　1．画像診断法
    　　2．核医学検査
    　III．悪性骨腫瘍の薬物療法および放射線療法
    　　1．病期分類
    　　2．薬物療法
    　　3．放射線療法
    　　4．医師主導臨床試験および治験
    　IV．免疫染色と遺伝子診断
    　　1．骨形成性腫瘍
    　　2．軟骨形成性腫瘍
    　　3．小円形細胞腫瘍
    　　4．破骨細胞型巨細胞に富む腫瘍
    　　5．その他
    　V．骨肉腫の組織学的効果判定と切除縁評価
    　　1．骨肉腫の組織学的効果判定
    　　2．切除縁評価
    　VI．病理診断報告書の記載
    　　1．病理診断報告書の構成
    　　2．病理診断
    　　3．病理所見（コメント）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 検鏡前の確認事項

P.5 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2020
 
P.10 掲載の参考文献
1) 日本整形外科学会骨・軟部腫瘍委員会 : 平成29年度全国骨腫瘍登録一覧表, 国立がん研究センター, 2017, pp28-35
 
2) Flanagan AM, Blay JY, Bovee JVMG, et al : Bone tumours : introduction. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp340-344
 
3) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumor Pathology, Series 4, Tumors of the Bones and Joints, AFIP, Washington DC, 2005, pp1-10
 
4) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadelphia, 2016, pp1-30
 
5) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp12-18
 
6) 森岡秀夫 : 概論 骨・軟部腫瘍診療のポイント. 森岡秀夫編 : 整形外科専門医になるための診療スタンダード 4 骨・軟部腫瘍および骨系統・代謝性疾患, 羊土社, 2009, pp12-42
 
P.13 掲載の参考文献
1) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumor Pathology, Series 4, Tumors of the Bones and Joints, AFIP, Washington DC, 2005
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012
 
3) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadalphia, 2016
 
4) 日本整形外科学会, 日本病理学会編 : 整形外科・病理 悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015
 
5) 日本病理学会 : ゲノム研究用・診療用病理組織検体取扱い規程, 羊土社, 2019
 

第2部 組織型と診断の実際

P.25 掲載の参考文献
1) Bovee JVMG, Bloem JL, Heymann D, et al : Osteochondroma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp356-358
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp137-146
 
3) Endo M, Hasegawa T, Tashiro T, et al : Bizarre parosteal osteochondromatous proliferation with a t (1 ; 17) translocation. Virchows Arch 447 : 99-102, 2005
 
4) Jones KB, Piombo V, Searby C, et al : A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A 107 : 2054-2059, 2010
 
5) Matsumoto K, Irie F, Mackem S, et al : A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci U S A 107 : 10932-10937, 2010
PubMed
6) Bovee JVMG, Bloem JL, Flanagan AM, et al : Enchondroma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp353-355
 
7) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp120-128
 
8) Bovee JVMG, Alman BA : Enchondromatosis. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5th ed), IARC Press, Lyon, 2020, pp506-509
 
9) Sakai Junior N, Abe KT, Formigli LM, et al : Cytogenetic findings in 14 benign cartilaginous neoplasms. Cancer Genet 204 : 180-186, 2011
PubMed
10) Dahlen A, Mertens F, Rydholm A, et al : Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol 16 : 1132-1140, 2003
PubMed
11) Amary MF, Bacsi K, Maggiani F, et al : IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224 : 334-343, 2011
 
12) Bridge JA, Cleven AHG, Tirabosco R : Periosteral chondroma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp351-352
 
13) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp128-132
 
P.31 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2020, pp338, 359-364
 
2) Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : WHO Classification of Tumours of Soft Tissue and Bone (4th ed), IARC Press, Lyon, 2013, pp240-241, 255-256, 262-263
 
3) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadelphia, 2016, pp246, 249-250, 400-438, 457
 
4) Weiss AP, Dorfman HD : S-100 protein in human cartilage lesions. J Bone Joint Surg Am 68 : 521-526, 1986
PubMed
5) Park HR, Park YK, Jang KT, et al : Expression of collagen type II, S100B, S100A2 and osteocalcin in chondroblastoma and chondromyxoid fibroma. Oncol Rep 9 : 1087-1091, 2002
PubMed
6) Konishi E, Nakashima Y, Iwasa Y, et al : Immunohistochemical analysis for Sox9 reveals the cartilaginous character of chondroblastoma and chondromyxoid fibroma of the bone. Hum Pathol 41 : 208-213, 2010
PubMed
7) Jaffe HL, Lichtenstein L : Benign chondroblastoma ofbone : a reinterpretation of the so-called calcifying or chondromatous giant cell tumor. Am J Pathol 18 : 969-991, 1942
PubMed
8) Behjati S, Tarpey PS, Presneau N, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013
PubMed
9) Presneau N, Baumhoer D, Behjati S, et al : Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res 1 : 113-123, 2015
PubMed
10) Baumhoer D, Amary F, Flanagan AM : An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer 58 : 88-99, 2019
PubMed
11) Jaffe HL, Lichtenstein L : Chondromyxoid fibroma of bone ; a distinctive benign tumor likely to be mistaken especially for chondrosarcoma. Arch Pathol 45 : 541-551, 1948
 
12) Nord KH, Lilljebjorn H, Vezzi F, et al : GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nat Genet 46 : 474-477, 2014
PubMed
P.42 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours (5th ed), Soft Tissue and Bone Tumours, IARC Press, Lyon, 2020
 
2) Unni KK, Inwards CY : Dahlin's Bone Tumors (6th ed), Lippincott Williams & Wilkins, Philadelphia, 2010
 
3) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumor Pathology, Series 4, Tumors of the Bones and Joints, AFIP, Washington DC, 2005
 
4) Bovee JVMG, Hogendoorn PCW, Wunder JS, et al : Cartilage tumours and bone development : molecular pathology and possible therapeutic targets. Nat Rev Cancer 10 : 481-488, 2010
 
5) Verdegaal SHM, Bovee JVMG, Pansuriya TC, et al : Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome : an international multicenter study of 161 patients. Oncologist 16 : 1771-1779, 2011
 
6) 日本整形外科学会骨軟部腫瘍委員会 : 平成28年度全国骨軟部腫瘍登録一覧表, 国立がん研究センター, 2017
 
7) Konishi E, Nakashima Y, Mano M, et al : Primary central chondrosarcoma of long bone, limb girdle and trunk : analysis of 174 cases by numerical scoring on histology. Pathol Int 65 : 468-475, 2015
PubMed
8) Nojima T, Unni KK, MacLeod RA, et al : Periosteal chondroma and periosteal chondrosarcoma. Am J Surg Pathol 9 : 666-677, 1985
 
9) Cleven AH, Zwartkruis E, Hogendoorn PC, et al : Periosteal chondrosarcoma : a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology 67 : 483-490, 2015
PubMed
10) Murphey MD, Flemming DJ, Boyea SR, et al : Enchondroma versus chondrosarcoma in the appendicular skeleton : differentiating features. Radiographics 18 : 1213-1237, Quiz 1244-1245, 1998
 
11) Crim J, Schmidt R, Layfield L, et al : Can imaging criteria distinguish enchondroma from grade 1 chondrosarcoma? Eur J Radiol 84 : 2222-2230, 2015
PubMed
12) Ahmed AR, Tan TS, Unni KK, et al : Secondary chondrosarcoma in osteochondroma : report of 107 patients. Clin Orthop Relat Res (411) : 193-206, 2003
PubMed
13) Bernard SA, Murphey MD, Flemming DJ, et al : Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology 255 : 857-865, 2010
 
14) Bjornsson J, McLeod RA, Unni KK, et al : Primary chondrosarcoma of long bones and limb girdles. Cancer 83 : 2105-2119, 1998
PubMed
15) Evans HL, Ayala AG, Romsdahl MM : Prognostic factors in chondrosarcoma of bone : a clinicopathologic analysis with emphasis on histologic grading. Cancer 40 : 818-831, 1977
 
16) Angelini A, Guerra G, Mavrogenis AF, et al : Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 106 : 929-937, 2012
PubMed
17) Lee FY, Mankin HJ, Fondren G, et al : Chondrosarcoma of bone : an assessment of outcome. J Bone Joint Surg Am 81 : 326-338, 1999
 
18) Gelderblom H, Hogendoorn PC, Dijkstra SD, et al : The clinical approach towards chondrosarcoma. Oncologist 13 : 320-329, 2008
PubMed
19) Eefting D, Schrage YM, Geirnaerdt MJ, et al : Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 33 : 50-57, 2009
PubMed
20) Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group : Reliability of histopathologic and radiologic grading of cartilaginous tumors. J Bone Joint Surg Am 89 : 2113-2123, 2007
 
21) Mirra JM, Gold R, Downs J, et al : A few histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (201) : 214-237, 1985
 
22) Geirnaerdt MJA, Hermans J, Bloem JL, et al : Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma. AJR Am J Roentgenol 169 : 1097-1104, 1997
 
23) Jaffe HL : Tumors and Tumorous Conditions of the Bones and Joints, Lea & Febiger, Philadelphia, 1958
 
24) Dahlin DC, Salvador AH : Chondrosarcomas of bones of the hands and feet-a study of 30 cases. Cancer 34 : 755-760, 1974
 
25) Dahlin DC, Henderson ED : Chondrosarcoma, a surgical and pathological problem ; review of 212 cases. J Bone Joint Surg Am 38-A : 1025-1038, 1956
 
26) Staals EL, Bacchini P, Mercuri M, et al : Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 89 : 987-993, 2007
PubMed
27) Amary MF, Bacsi K, Maggiani F, et al : IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224 : 334-343, 2011
 
28) Amary MF, Damato S, Halai D, et al : Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43 : 1262-1265, 2011
PubMed
29) Guilhamon P, Eskandarpour M, Halai D, et al : Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun 4 : 2166, 2013
PubMed
30) Tarpey PS, Behjati S, Cooke SL, et al : Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 45 : 923-926, 2013
PubMed
31) Tiet TD, Hopyan S, Nadesan P, et al : Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 168 : 321-330, 2006
PubMed
32) Bridge JA, Nelson M, Orndal C, et al : Clonal karyotypic abnormalities of the hereditary multiple exostoses chromosomal loci 8q24.1 (EXT1) and 11p11-12 (EXT2) in patients with sporadic and hereditary osteochondromas. Cancer 82 : 1657-1663, 1998
PubMed
33) Hameetman L, Szuhai K, Yavas A, et al : The role of EXT1 in nonhereditary osteochondroma : identification of homozygous deletions. J Natl Cancer Inst 99 : 396-406, 2007
PubMed
34) de Andrea CE, Reijnders CM, Kroon HM, et al : Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 31 : 1095-1104, 2012
PubMed
35) de Andrea CE, Zhu JF, Jin H, et al : Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. J Pathol 236 : 210-218, 2015
PubMed
P.55 掲載の参考文献
1) Inwards CY, Bloem JL, Hogendoorn PCW : Dedifferentiated chondrosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp388-390
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp181-186
 
3) Littrell LA, Wenger DE, Wold LE, et al : Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas : a retrospective review of 174 de novo cases. Radiographics 24 : 1397-1409, 2004
 
4) Knosel T, Werner M, Jung A, et al : Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma? Pathol Res Pract 210 : 194-197, 2014
PubMed
5) Makise N, Sekimizu M, Konishi E, et al : H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol 32 : 435-445, 2019
PubMed
6) Shon W, Folpe AL, Fritchie KJ : ERG expression in chondrogenic bone and soft tissue tumours. J Clin Pathol 68 125-129, 2015
PubMed
7) Amary MF, Bacsi K, Maggiani F, et al : IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224 : 334-343, 2011
 
8) Morrison C, Radmacher M, Mohammed N, et al : MYC amplification and polysomy 8 in chondrosarcoma : array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 23 : 9369-9376, 2005
PubMed
9) Bovee JV, Cleton-Jansen AM, Rosenberg C, et al : Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 189 : 454-462, 1999
PubMed
10) Bridge JA, DeBoer J, Travis J, et al : Simultaneous interphase cytogenetic analysis and fluorescence immunophenotyping of dedifferentiated chondrosarcoma. Implications for histopathogenesis. Am J Pathol 144 : 215-220, 1994
PubMed
11) Fanburg-Smith JC, de Pinieux G, Ladanyi M : Mesenchymal chondrosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp385-387
 
12) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp193-202
 
13) Frezza AM, Cesari M, Baumhoer D, et al : Mesenchymal chondrosarcoma : prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 51 : 374-381, 2015
 
14) Fanburg-Smith JC, Auerbach A, Marwaha JS, et al : Reappraisal of mesenchymal chondrosarcoma : novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases. Hum Pathol 41 : 653-662, 2010
PubMed
15) Wang L, Motoi T, Khanin R, et al : Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 51 : 127-139, 2012
PubMed
16) Nakayama R, Miura Y, Ogino J, et al : Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma. Pathol Int 62 : 823-826, 2012
PubMed
17) Nyquist KB, Panagopoulos I, Thorsen J, et al : Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t (1 ; 5) (q42 ; q32) in mesenchymal chondrosarcoma. PLoS One 7 : e49705, 2012
 
18) Matsuyama A, Shiba E, Umekita Y, et al : Clinicopathologic diversity of undifferentiated sarcoma with BCOR-CCNB3 fusion : analysis of 11 cases with a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017
PubMed
19) Siegele B, Roberts J, Black JO, et al : DUX4 immunohistochemistry is a highly sensitive and specific marker for CIC-DUX4 fusion-positive round cell tumor. Am J Surg Pathol 41 : 423-429, 2017
PubMed
20) Baumhoer D, Bloem JL, Oda Y : Clear cell chondrosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp383-384
 
21) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp186-193
 
22) Collins MS, Koyama T, Swee RG, et al : Clear cell chondrosarcoma : radiographic, computed tomographic, and magnetic resonance findings in 34 patients with pathologic correlation. Skeletal Radiol 32 : 687-694, 2003
PubMed
23) Behjati S, Tarpey PS, Presneau N, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013
PubMed
24) Matsuura S, Ishii T, Endo M, et al : Epithelial and cartilaginous differentiation in clear cell chondrosarcoma. Hum Pathol 44 : 237-243, 2013
PubMed
25) Park YK, Cho CH, Chi SG, et al : Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma. Int J Oncol 19 : 749-753, 2001
 
26) Park YK, Park HR, Chi SG, et al : Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol 19 : 353-357, 2001
 
27) Meijer D, de Jong D, Pansuriya TC, et al : Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 51 : 899-909, 2012
PubMed
P.62 掲載の参考文献
1) Jaffe HL, Mayer L : An osteoblastic osteoid tissue forming tumor of a metacarpal bone. Arch Surg 24 : 550-564, 1932
 
2) Jaffe HL : "Osteoid-osteoma" : a benign osteoblastic tumor composed of osteoid and atypical bone. Arch Surg 31 : 709-728, 1935
 
3) Jaffe HL : Benign osteoblastoma. Bull Hosp Joint Dis 17 : 141-151, 1956
PubMed
4) Lichtenstein L : Benign osteoblastoma ; a category of osteoid- and bone-forming tumors other than classical osteoid osteoma, which may be mistaken for giant-cell tumor or osteogenic sarcoma. Cancer 9 : 1044-1052, 1956
PubMed
5) McHugh JB, Mukherji SK, Lucas DR : Sino-orbital osteoma : a clinicopathologic study of 45 surgically treated cases with emphasis on tumors with osteoblastoma-like features. Arch Pathol Lab Med 133 : 1587-1593, 2009
PubMed
6) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumor Pathology, Series 4, Tumors of the Bones and Joints, AFIP, Washington DC, 2005, pp119-135
 
7) Makley JT, Dunn MJ : Prostaglandin synthesis by osteoid osteoma. Lancet 2 : 42, 1982
PubMed
8) Mungo DV, Zhang X, O'Keefe RJ, et al : COX-1 and COX-2 expression in osteoid osteomas. J Orthop Res 20 : 159-162, 2002
 
9) Fittall MW, Mifsud W, Pillay N, et al : Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9 : 2150, 2018
PubMed
10) Amary F, Markert E, Berisha F, et al : FOS expression in osteoid osteoma and osteoblastoma : A valuable ancillary diagnostic tool. Am J Surg Pathol 43 : 1661-1667, 2019
PubMed
11) Lam SW, Cleven AHG, Kroon HM, et al : Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Arch 476 : 455-463, 2020
PubMed
12) Dor fman HD, Weiss SW : Borderline osteoblastic tumors : problems in the differential diagnosis of aggressive osteoblastoma and low-grade osteosarcoma. Semin Diagn Pathol 1 : 215-234, 1984
 
13) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadelphia 2016, pp144-199
 
14) Unni KK, Inwards CY : Dahlin's Bone Tumors (6th ed), Lippincott Williams & Wilkins, Philadelphia, 2010, pp98-121
 
P.72 掲載の参考文献
1) Kager L, Zoubek A, Kastner U, et al : Skip metastases in osteosarcoma : experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24 : 1535-1541, 2006
 
2) Suehara Y, Alex D, Bowman A, et al : Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res 25 : 6346-6356, 2019
PubMed
3) Yoshida A, Ushiku T, Motoi T, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012
PubMed
4) Amary F, Berisha F, Ye H, et al : H3F3A (Histone 3.3) G34W immunohistochemistry : a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 41 : 1059-1068, 2017
PubMed
5) Davis JL, Horvai AE : Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other highgrade primary bone sarcomas. Histopathology 69 : 84-90, 2016
PubMed
6) Kerr DA, Lopez HU, Deshpande V, et al : Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol 37 : 787-795, 2013
PubMed
7) Gambarotti M, Dei Tos AP, Vanel D, et al : Osteoblastomalike osteosarcoma : high-grade or low-grade osteosarcoma? Histopathology 74 : 494-503, 2019
PubMed
8) Lam SW, Cleven AHG, Kroon HM, et al : Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Arch 476 : 455-463, 2020
PubMed
P.84 掲載の参考文献
1) Matsuno T, Unni KK, McLeod RA, et al : Telangiectatic osteogenic sarcoma. Cancer 38 : 2538-2547, 1976
PubMed
2) Baumhoer D, Bohling TO, Cates JMM, et al : Osteosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2019, pp403-409
 
3) Oliveira AM, Okada K, Squire J : Telangiectatic osteosarcoma. in Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : "World Health Organization Classification of Tumours of Soft Tissue and Bone" (4 th ed), IARC Press, Lyon, 2013, pp289-290
 
4) Matsuno T, Okada K, Knuutila S : Telangiectatic osteosarcoma. in Fletcher CDM, Unni KK, Mertens F (eds) : "World Health Organization Classification of Tumours, Pathology and Genetics Tumours of Soft Tissue and Bone" (3rd ed), IARC Press, Lyon, 2002, pp271-272
 
5) 石田剛 : 特殊型骨肉腫. 野島孝之, 小田義直編 : 腫瘍病理鑑別診断アトラス骨腫瘍, 文光堂, 2016, pp65-75
 
6) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp82-87
 
7) 石田剛 : 骨形成性腫瘍の病理. 病理と臨床 38 : 311-319, 2020
Medical*Online
8) Martin JW, Squire JA, Zielenska M : The genetics of osteosarcoma. Sarcoma 2012 : 627254, 2012
PubMed
9) Sim FH, Unni KK, Beabout JW, et al : Osteosarcoma with small cells simulating Ewing's tumor. J Bone Joint Surg Am 61 : 207-215, 1979
PubMed
10) Ayala AG, Ro JY, Raymond AK, et al : Small cell osteosarcoma. A clinicopathologic study of 27 cases. Cancer 64 : 2162-2173, 1989
PubMed
11) Forest M, De Pinieux G, Knuutila S : Secondary osteosarcoma. in Fletcher CDM, Unni KK, Mertens F (eds) : "World Health Organization Classification of Tumours, Pathology and Genetics Tumours of Soft Tissue and Bone" (3rd ed), IARC Press, Lyon, 2002, pp277-278
 
12) Rosenberg AE, Cleton-Jansen AM, de Pinieux G, et al : Conventional osteosarcoma. in Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : "World Health Organization Classification of Tumours of Soft Tissue and Bone" (4 th ed), IARC Press, Lyon, 2013, pp282-288
 
13) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp115-117
 
14) Deyrup AT, Montag AG, Inwards CY, et al : Sarcomas arising in Paget disease of bone : a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med 131 : 942-946, 2007
PubMed
15) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp260-274
 
16) Unni KK, Dahlin DC, McLeod RA, et al : Intraosseous well-differentiated osteosarcoma. Cancer 40 : 1337-1347, 1977
PubMed
17) Inwards CY, Knuutila S : Low grade central osteosarcoma. in Fletcher CDM, Unni KK, Mertens F (eds) : "World Health Organization Classification of Tumours, Pathology and Genetics Tumours of Soft Tissue and Bone" (3 rd ed), IARC Press, Lyon, 2002, pp275-276
 
18) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp87-93
 
19) Yoshida A, Ushiku T, Motoi T, et al : Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 23 : 1279-1288, 2010
PubMed
20) Yoshida A, Ushiku T, Motoi T, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012
PubMed
21) Yoshida A, Bredella MA, Gambarotti M, et al : Low-grade central osteosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2019, pp400-402
 
P.93 掲載の参考文献
1) Wang J, Nord KH, O'Donnell PG, et al : Parosteal osteosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp410-413
 
2) 小田義直, 恒吉正澄 : 2. 良悪鑑別および悪性度が問題となる疾患 (2) 骨肉腫と良性病変との鑑別. 病理と臨床 20 : 795-811, 2002
 
3) Okada K, Frassica FJ, Sim FH, et al : Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am 76 : 366-378, 1994
PubMed
4) Sheth DS, Yasko AW, Raymond AK, et al : Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer 78 : 2136-2145, 1996
PubMed
5) Ruengwanichayakun P, Gambarotti M, Frisoni T, et al : Parosteal osteosarcoma : a monocentric retrospective analysis of 195 patients. Hum Pathol 91 : 11-18, 2019
PubMed
6) Hang JF, Chen PC : Parosteal osteosarcoma. Arch Pathol Lab Med 138 : 694-699, 2014
PubMed
7) He X, Pang Z, Zhang X, et al : Consistent amplification of FRS2 and MDM2 in low-grade osteosarcoma : A genetic study of 22 cases with clinicopathologic analysis. Am J Surg Pathol 42 : 1143-1155, 2018
PubMed
8) Yoshida A, Ushiku T, Motoi T, et al : Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 23 : 1279-288, 2010
PubMed
9) Dujardin F, Binh MB, Bouvier C, et al : MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 24 : 624-637, 2011
PubMed
10) Yoshida A, Ushiku T, Motoi T, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012
PubMed
11) Bonar SFM, Klein MJ, O'Donnell PG : Perioseal osteosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp414-416
 
12) Oda Y, Hashimoto H, Tsuneyoshi M, et al : Case report 793. Periosteal osteosarcoma of the clavicle. Skeletal Radiol 22 : 375-377, 1993
PubMed
13) Cesari M, Alberghini M, Vanel D, et al : Periosteal osteosarcoma : a single-institution experience. Cancer 117 : 1731-1735, 2011
PubMed
14) Righi A, Gambarotti M, Benini S, et al : MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol 46 : 549-553, 2015
PubMed
15) Radig K, Schneider-Stock R, Haeckel C, et al : p53 gene mutations in osteosarcomas of low-grade malignancy. Hum Pathol 29 : 1310-1316, 1998
PubMed
16) Klein MJ, Bonar SFM, O'Donnell PG : High-grade surface osteosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp417-418
 
17) Staals EL, Bacchini P, Bertoni F : High-grade surface osteosarcoma : a review of 25 cases from the Rizzoli Institute. Cancer 112 : 1592-1599, 2008
PubMed
18) Noble-Topham SE, Burrow SR, Eppert K, et al : SAS is amplified predominantly in surface osteosarcoma. J Orthop Res 14 : 700-705, 1996
PubMed
P.97 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2020, p422, 447, 448
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp238-249
 
3) Kadowaki H, Oyama Y, Nishida H, et al : A case of desmoplastic fibroma of bone with CTNNB1 point mutation. Oral Surg Oral Med Oral Pathol Oral Radiol 129 : e230-e233, 2020
PubMed
4) Baumhoer D, Kovac M, Sperveslage J, et al : Activating mutations in the MAP-kinase pathway define non-ossifying fibroma of bone. J Pathol 248 : 116-122, 2019
 
P.101 掲載の参考文献
1) Jaffe HL : Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-oseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol 6 : 159-175, 1953
PubMed
2) Ackerman LV, Spjut HJ : Giant cell reaction in tumors of bone and cartilage. in Spjut HJ, Dorfman HD, Fechner RE (eds) : "Atlas of Tumor Pathology, Section II Fascicle 4", AFIP, Washington DC, 1962, p282
 
3) Forsyth R, Jundt G : Giant cell lesion of the small bones. in Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : "World Health Organization Classification of Tumours of Soft Tissue and Bone" (4 th ed), IARC Press, Lyon, 2013, p320
 
4) Agaram NP, Bredella MA : Aneurysmal bone cyst. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5th ed), IARC Press, Lyon, 2020, pp437-439
 
5) Raubenheimer E, Jordan RC : Central giant cell granuloma. in El-Naggar AK, Chan JKC, Grandis JR, et al (eds) : "World Health Organization Classification of Head and Neck Tumours" (4 th ed), IARC Press, Lyon, 2017, p256
 
6) Agaram NP, LeLoarer FV, Zhang L, et al : USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol 45 : 1147-1152, 2014
 
7) Johnsson A, Collin A, Rydholm A, et al : Unstable translocation (8 ; 22) in a case of giant cell reparative granuloma. Cancer Genet Cytogenet 177 : 59-63, 2007
 
8) Angelini A, Pagliarini E, Belluzzi E, et al : Giant cell reparative granuloma of the scapula : report of a case and literature review. Skeletal Radiol 48 : 1293-1298, 2019
PubMed
9) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp417-423
 
10) Murphey MD, Nomikos GC, Flemming DJ, et al : From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone : radiologic-pathologic correlation. Radiographics 21 : 1283-1309, 2001
PubMed
11) Zhou J, Zheng S, Zhou L, et al : Pathologic evaluation of the solid variant of aneurysmal bone cysts with USP6 rearrangement with an emphasis on the frequent diagnostic pitfalls. Pathol Int 70 : 502-512, 2020
PubMed
12) Oda Y, Tsuneyoshi M, Shinohara N : "Solid" variant of aneurysmal bone cyst (extragnathic giant cell reparative granuloma) in the axial skeleton and long bones. A study of its morphologic spectrum and distinction from allied giant cell lesions. Cancer 70 : 2642-2649, 1992
 
13) Angelini A, Ruggieri P : Response to a letter to the editor concerning "Giant Cell Reparative Granuloma of the Scapula : report of a case and literature review". Skeletal Radiol 49 : 339, 2020
 
P.104 掲載の参考文献
1) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadelphia, 2016, pp1055-1076
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp410-417
 
3) Oliveira AM, Perez-Atayde AR, Inwards CY, et al : USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 165 : 1773-1780, 2004
PubMed
4) Li L, Bui MM, Zhang M, et al : Validation of fluorescence in situ hybridization testing of USP6 gene rearrangement for diagnosis of primary aneurysmal bone cyst. Ann Clin Lab Sci 49 : 590-597, 2019
 
5) Agaram NP, LeLoarer FV, Zhang L, et al : USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol 45 : 1147-1152, 2014
 
6) Rehkamper J, Steinestel K, Jeiler B, et al : Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy. Oncotarget 9 : 30106-30114, 2018
 
P.110 掲載の参考文献
1) Fletcher CDM, Bridge JA, Hogendoorn PCW, et al : "World Health Organization Classification of Tumours of Soft Tissue and Bone" (4 th ed), IARC Press, Lyon, 2013
 
2) Al-Ibraheemi A, Inwards CY, Zreik RT, et al : Histologic spectrum of giant cell tumor (GCT) of bone in patients 18 years of age and below : A study of 63 patients. Am J Surg Pathol 40 : 1702-1712, 2016
 
3) Czerniak B : Dorfman and Czerniak's Bone Tumors (2nd ed), Elsevier, Philadelphia, 2016
 
4) Palmerini E, Picci P, Reichardt P, et al : Malignancy in giant cell tumor of bone : A review of the literature. Technol Cancer Res Treat 18 : 1533033819840000, 2019
PubMed
5) Domovitov SV, Healey JH : Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 17 : 694-701, 2010
PubMed
6) Bahk WJ, Mirra JM : Pseudoanaplastic tumors of bone. Skeletal Radiol 33 : 641-648, 2004
PubMed
7) Wojcik J, Rosenberg AE, Bredella MA, et al : Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol 40 : 72-80, 2016
PubMed
8) Behjati S, Tarpey PS, Presneau N, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013
PubMed
9) Ogura K, Hosoda F, Nakamura H, et al : Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone. Genes Chromosom Cancer 56 : 711-718, 2017
PubMed
10) Toledo RA, Qin Y, Cheng ZM, et al : Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res 22 : 2301-2310, 2016
PubMed
11) Bjerke L, Mackay A, Nandhabalan M, et al : Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3 : 512-519, 2013
PubMed
12) Yoshida KI, Nakano Y, Honda-Kitahara M, et al : Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol 32 : 1751-1761, 2019
 
13) Amary F, Berisha F, Ye H, et al : H3F3A (histone 3.3) G34W immunohistochemistry : A reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 41 : 1059-1068, 2017
PubMed
14) Yamamoto H, Iwasaki T, Yamada Y, et al : Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 73 : 41-50, 2018
PubMed
15) Kato I, Furuya M, Matsuo K, et al : Giant cell tumours of bone treated with denosumab : histological, immunohistochemical and H3F3A mutation analyses. Histopathology 72 : 914-922, 2018
PubMed
16) Brcic I, Yamani F, Inwards CY, et al : Giant cell tumor of bone with cartilage matrix : A clinicopathologic study of 17 cases. Am J Surg Pathol 44 : 748-756, 2020
PubMed
17) Luke J, von Baer A, Schreiber J, et al : H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 71 : 125-133, 2017
PubMed
18) Amary MF, Berisha F, Mozela R, et al : The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology 69 : 121-127, 2016
 
19) Agaram NP, LeLoarer FV, Zhang L, et al : USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol 45 : 1147-1152, 2014
 
20) Lee JC, Su SY, Changou CA, et al : Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29 : 1335-1346, 2016
 
P.120 掲載の参考文献
1) Fletcher CDM, Unni KK, Mertens F (eds) : World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone (3rd ed), IARC Press, Lyon, 2002
 
2) Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : World Health Organization Classification of Tumours of Soft Tissue and Bone (4th ed), IARC Press, Lyon, 2013
 
3) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2020
 
4) Yamaguchi T, Suzuki S, Ishiiwa H, et al : Intraosseous benign notochordal cell tumours : overlooked precursors of classic chordomas? Histopathology 44 : 597-602, 2004
PubMed
5) Ulich TR, Mirra JM : Ecchordosis physaliphora vertebralis. Clin Orthop Relat Res (163) : 282-289, 1982
PubMed
6) Darby AJ, Cassar-Pullicino VN, McCall IW, et al : Vertebral intra-osseous chordoma or giant notochordal rest? Skeletal Radiol 28 : 342-346, 1999
PubMed
7) Mirra JM, Brien EW : Giant notochordal hamartoma of intraosseous origin : a newly reported benign entity to be distinguished from chordoma. Report of two cases. Skeletal Radiol 30 : 698-709, 2001
PubMed
8) Kyriakos M, Totty WG, Lenke LG : Giant vertebral notochordal rest : a lesion distinct from chordoma : discussion of an evolving concept. Am J Surg Pathol 27 : 396-406, 2003
 
9) Yamaguchi T, Iwata J, Sugihara S, et al : Distinguishing benign notochordal cell tumors from vertebral chordoma. Skeletal Radiol 37 : 291-299, 2008
PubMed
10) Yamaguchi T, Yamato M, Saotome K : First histologically confirmed case of a classic chordoma arising in a precursor benign notochordal lesion : differential diagnosis of benign and malignant notochordal lesions. Skeletal Radiol 31 : 413-418, 2002
 
11) Deshpande V, Nielsen GP, Rosenthal DI, et al : Intraosseous benign notochord cell tumors (BNCT) : further evidence supporting a relationship to chordoma. Am J Surg Pathol 31 : 1573-1577, 2007
PubMed
12) 飯田俊, 山口岳彦, 今田浩生, 他 : 胎児・小児脊椎にみられる遺残脊索組織の存在部位に関する組織学的検討. 日本病理学会会誌 107 : 383, 2018
 
13) Larousserie F, Drape JL, Chevrot A, et al : Case 32. International Skeletal Society Members' Meeting 2014
 
14) Ahmed SK, Murata H, Draf W : Clivus chordoma : Is it enough to image the primary site? Skull Base 20 : 111-113, 2010
PubMed
15) Yamaguchi T : On "clivus chordoma : Is it enough to image the primary site?" (Skull Base 2010 ; 20 : 111-113). Skull Base 21 : 277-278, 2011
PubMed
16) Vujovic S, Henderson S, Presneau N, et al : Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209 : 157-165, 2006
PubMed
17) Kikuchi Y, Yamaguchi T, Kishi H, et al : Pulmonary tumor with notochordal differentiation : report of 2 cases suggestive of benign notochordal cell tumor of extraosseous origin. Am J Surg Pathol 35 : 1158-1164, 2011
PubMed
18) Takahashi Y, Motoi T, Harada M, et al : Extraosseous benign notochordal cell tumor originating in the lung : a case report. Medicine (Baltimore) 94 : e366, 2015
 
19) Shintaku M, Kikuchi R : Benign notochordal cell tumor of the lung : Report of a case. Pathol Int 70 : 871-875, 2020
PubMed
20) Carter JM, Wenger DE, Rose PS, et al : Atypical notochordal cell tumors : a series of notochordal-derived tumors that defy current classification schemes. Am J Surg Pathol 41 : 39-48, 2017
PubMed
21) Matsubayashi J, Sato E, Nomura M, et al : A case of paravertabral mediastinal chordoma without bone destruction. Skeletal Radiol 41 : 1641-1644, 2012
 
22) Akiyama T, Ogura K, Gokita T, et al : Analysis of the infiltrative features of chordoma : the relationship between micro-skip metastasis and postoperative outcomes. Ann Surg Oncol 25 : 912-919, 2018
PubMed
23) Imai R, Kamada T, Sugahara S, et al : Carbon ion radiotherapy for sacral chordoma. Br J Radiol 84 : S48-S54, 2011
PubMed
24) Nishida Y, Kamada T, Imai R, et al : Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys 79 : 110-116, 2011
PubMed
25) Matsumoto T, Imagama S, Ito Z, et al : Total spondylectomy following carbon ion radiotherapy to treat chordoma of the mobile spine. Bone Joint J 95B : 1392-1395, 2013
 
26) Imai R, Kamada T, Araki N, et al : Carbon ion radiation therapy for unresectable sacral chordoma : an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95 : 322-327, 2016
PubMed
27) Yamaguchi T, Imada H, Iida S, et al : Notochordal tumors : An update on molecular pathology with therapeutic implications. Surg Pathol Clin 10 : 637-656, 2017
PubMed
28) Tirabosco R, Mangham DC, Rosenberg AE, et al : Brachyury expression in extra-axial skeletal and soft tissue chordomas : a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 32 : 572-580, 2008
PubMed
29) Lalam R, Cassar-Pullicino VN, McClure J, et al : Entrapped intralesional marrow : a hitherto undescribed imaging feature of benign notochordal cell tumour. Skeletal Radiol 41 : 725-731, 2012
 
P.125 掲載の参考文献
1) Hameed M, Bloem JL, Righi A : Haemangioma of bone. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp426-427
 
2) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp281-285
 
3) Bovee JVMG, Rosenberg AE : Epithelioid haemangioma of bone. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp428-430
 
4) Errani C, Zhang L, Panicek DM, et al : Epithelioid hemangioma of bone and soft tissue : a reappraisal of a controversial entity. Clin Orthop Relat Res 470 : 1498-1506, 2012
 
5) Nielsen GP, Srivastava A, Kattapuram S, et al : Epithelioid hemangioma of bone revisited : A study of 50 cases. Am J Surg Pathol 33 : 270-277, 2009
PubMed
6) Hung YP, Fletcher CD, Hornick JL : FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma. Am J Surg Pathol 41 : 596-606, 2017
PubMed
7) van IJzendoorn DG, de Jong D, Romagosa C, et al : Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes Cancer 54 : 565-574, 2015
PubMed
P.131 掲載の参考文献
1) Bovee, JVMG, Antonescu CR, Rosenberg AE : Epithelioid haemangioendothelioma of bone. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IRAC Press, Lyon, 2020, pp431-433
 
2) Weissferdt A, Moran CA : Epithelioid hemangioendothelioma of the bone : a review and update. Adv Anat Pathol 21 : 254-259, 2014
 
3) Shibuya R, Matsuyama A, Shiba E, et al : CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 67 : 827-835, 2015
PubMed
4) Mendlick MR, Nelson M, Pickering D, et al : Translocation t(1 ; 3) (p36.3 ; q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 25 : 684-687, 2001
 
5) 石田剛 : 骨脈管性腫瘍の臨床病理. 病理と臨床 27 : 156-168, 2009
Medical*Online
6) Evans HL, Raymond AK, Ayala AG : Vascular tumors of bone : a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol 34 : 680-689, 2003
 
7) Huang SC, Zhang L, Sung YS, et al : Frequent FOS gene rearrangements in epithelioid hemangioma : A molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol 39 : 1313-1321, 2015
PubMed
8) Honick JL, Fletcher CD : Pseudomyogenic hemangioendothelioma : a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 35 : 190-201, 2011
 
9) Hung YP, Fletcher CDM, Hornick JL : FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma. Am J Surg Pathol 41 : 596-606, 2017
 
10) Lau K, Massad M, Pollack C, et al : Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement : insights from an internet registry in the study of a rare cancer. Chest 140 : 1312-1318, 2011
 
11) Kleer CG, Unni KK, McLeod RA : Epithelioid hemangioendothelioma of bone. Am J Surg Pathol 20 : 1301-1311, 1996
PubMed
12) 福永真治 : 類上皮血管内皮腫および血管肉腫. 野島孝之, 小田義直編 : 腫瘍病理鑑別診断アトラス 骨腫瘍. 文光堂, 2016, pp109-114
 
13) Bovee JVMG, Rosenberg AE : Angiosarcoma. in Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : "World Health Organization Classification of Tumours of Soft Tissue and Bone" (4 th ed), IRAC Press, Lyon, 2013, pp337-338
 
14) Dunlap JB, Magenis RE, Davis C, et al : Cytogenetic analysis of a primary bone angiosarcoma. Cancer Genet Cytogenet 194 : 1-3, 2009
PubMed
15) Manner J, Radlwimmer B, Hohenberger P, et al : MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 176 : 34-39, 2010
PubMed
16) Verbeke SL, Bertoni F, Bacchini P, et al : Distinct histological features characterize primary angiosarcoma of bone. Histopathology 58 : 254-264, 2011
PubMed
P.134 掲載の参考文献
1) Noordin S, Allana S, Umer M, et al : Unicameral bone cysts : Current concepts. Ann Med Surg (Lond) 34 : 43-49, 2018
PubMed
2) Aycan OE, Camurcu IY, Ozer D, et al : Unusual localizations of unicameral bone cysts and aneurysmal bone cysts : A retrospective review of 451 cases. Acta Orthop Belg 81 : 209-212, 2015
PubMed
3) Mascard E, Gomez-Brouchet A, Lambot K : Bone cysts : unicameral and aneurysmal bone cyst. Orthop Traumatol Surg Res 101 : S119-S127, 2015
PubMed
4) Takada J, Hoshi M, Oebisu N, et al : A comparative study of clinicopathological features between simple bone cysts of the calcaneus and the long bone. Foot Ankle Int 35 : 374-382, 2014
 
5) Liu Q, He H, Zeng H, et al : Active unicameral bone cysts : control firstly, cure secondly. J Orthop Surg Res 14 : 275, 2019
PubMed
6) Miu A : Etiological aspects of solitary bone cysts : comments regarding the presence of the disease in two brothers. Is the genetic theory sustainable or is it pure coincidence? -Case report. J Med Life 8 : 509-512, 2015
PubMed
7) Doganavsargil B, Ayhan E, Argin M, et al : Cystic bone lesions : histopathological spectrum and diagnostic challenges. Turk Patoloji Derg 31 : 95-103, 2015
PubMed
P.139 掲載の参考文献
1) Siegal GP, Bloem JL, Cates JMM, et al : Fibrous dysplasia. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumour, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp472-474
 
2) Vigorita VJ : Orthopaedic Pathology (2nd ed), Lippincott Williams & Wilkins, Philadelphia, 2007, pp319-328
 
3) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp260-274
 
4) Lichtenstein L : Polyostotic fibrous dysplasia. Arch Surg 36 : 874-898, 1938
 
5) Lichtenstein L, Jaffe HL : Fibrous dysplasia of bone. A condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Path 33 : 777-816, 1942
 
6) Ishida T, Dorfman HD : Massive chondroid differentiation in fibrous dysplasia of bone (fibrocartilaginous dysplasia). Am J Surg Pathol 17 : 924-930, 1993
PubMed
7) DiCaprio MR, Enneking WF : Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 87 : 1848-1864, 2005
PubMed
8) Weinstein LS, Shenker A, Gejman PV, et al : Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325 : 1688-1695, 1991
PubMed
9) Lee SE, Lee EH, Park H, et al : The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia : meta-analysis of 168 sporadic cases. Hum Pathol 43 : 1234-1242, 2012
PubMed
10) Park YK, Unni KK, Beabout JW, et al : Oncogenic osteomalacia : a clinicopathologic study of 17 bone lesions. J Korean Med Sci 9 : 289-298, 1994
PubMed
11) Riminucci M, Collins MT, Fedarko NS, et al : FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112 : 683-692, 2003
PubMed
12) Ishida T, Iijima T, Kikuchi F, et al : A clinicopathological and immunohistochemical study of osteofibrous dysplasia, differentiated adamantinoma, and adamantinoma of long bones. Skeletal Radiol 21 : 493-502, 1992
PubMed
13) Maki M, Saitoh K, Horiuchi H, et al : Comparative study of fibrous dysplasia and osteofibrous dysplasia : histopathological, immunohistochemical, argyrophilic nucleolar organizer region and DNA ploidy analysis. Pathol Int 51 : 603-611, 2001
PubMed
14) Yoshida A, Ushiku T, Motoi T, et al : Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 23 : 1279-1288, 2010
PubMed
P.143 掲載の参考文献
1) Lichtenstein L : Histiocytosis X (eosinophilic granuloma of bone, Letterer-Siwe disease, and Schueller-Christian disease). Further observations of pathological and clinical importance. J Bone Joint Surg Am 46 : 76-90, 1964
PubMed
2) Unni KK, Inwards CY : Dahlin's Bone Tumors (6th ed), Lippincott Williams & Wilkins, Philadelphia, 2010, pp358-361
 
3) Pileri AA, Cheuk W, Picarsic J : Langerhans cell histiocytosis. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp492-494
 
4) Wester SM, Beabout JW, Unni KK, et al : Langerhans' cell granulomatosis (histiocytosis X) of bone in adults. Am J Surg Pathol 6 : 413-426, 1982
PubMed
5) Allen CE, Merad M, McClain KL : Langerhans-cell histiocytosis. N Engl J Med 379 : 856-868, 2018
PubMed
6) Willman CL, Busque L, Griffith BB, et al : Langerhans' -cell histiocytosis (histiocytosis X) -a clonal proliferative disease. N Engl J Med 331 : 154-160, 1994
PubMed
7) Yu RC, Chu C, Buluwela L, et al : Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343 : 767-768, 1994
PubMed
8) Badalian-Very G, Vergilio JA, Degar BA, et al : Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol 156 : 163-172, 2012
PubMed
9) Brown NA, Furtado LV, Betz BL, et al : High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124 : 1655-1658, 2014
PubMed
10) Chen W, Wang J, Wang E, et al : Detection of clonal lymphoid receptor gene rearrangements in Langerhans cell histiocytosis. Am J Surg Pathol 34 : 1049-1057, 2010
PubMed
P.146 掲載の参考文献
1) Campanacci M : Osteofibrous dysplasia of long bones. A new clinical entity. Ital J Orthop Traumatol 2 : 221-237, 1976
 
2) Nielsen GP, Hogendoom PCW : Osteofibrous dysplasia. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp460-462
 
3) Kempson RL : Ossifying fibroma of the long bones. A light and eloctron microscopic study. Arch Pathol 82 : 218-233, 1966
 
4) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumour Pathology, Series 4, Tumours of the Bones and Joints, AFIP, Washington DC, 2005
 
5) 石田剛 : 骨腫瘍の病理, 文光堂, 2012
 
6) Dorfman HD, Czerniak B : Bone Tumors, Mosby, St Louis, 1998
 
7) Campanacci M, Laus M : Osteofibrous dysplasia of the tibia and fibula. J Bone Joint Surg Am 63 : 367-375, 1981
PubMed
8) Nakashima Y, Yamamuro T, Fujiwara Y, et al : Osteofibrous dysplasia (ossifying fibroma of long bones). A study of 12 cases. Cancer 52 : 909-914, 1983
 
P.150 掲載の参考文献
1) 町並陸生, 石田剛, 菊地文史, 他 : 骨アダマンチノーマの病理, とくに骨線維性異形成との関連に注目して. 病理と臨床 10 : 1374-1384, 1992
 
2) Unni KK, Inwards CY, Bridge JA, et al : AFIP Atlas of Tumor Pathology, Series 4, Tumors of the Bones and Joints, AFIP, Washington DC, 2005 pp299-307
 
3) Kikuchi Y, Kishimoto T, Ota S, et al : Adamantinoma-like Ewing family tumor of soft tissue associated with the vagus nerve : a case report and review of literature. Am J Surg Pathol 37 : 772-779, 2013
PubMed
4) Gleason BC, Liegl-Atzwanger B, Kozakewich HP, et al : Osteofibrous dysplasia and adamantinoma in children and adolescents : a clinicopathologic reappraisal. Am J Surg Pathol 32 : 363-376, 2008
PubMed
5) Ali NM, Niada S, Morris MR, et al : Comprehensive molecular characterization of adamantinoma and OFD-like adamantinoma bone tumors. Am J Surg Pathol 43 : 965-974, 2019
PubMed
P.159 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020
 
2) Rooper LM, Jo VY, Antonescu CR, et al : Adamantinoma-like Ewing sarcoma of the salivary glands : a newly recognized mimicker of basaloid salivary carcinomas. Am J Surg Pathol 43 : 187-194, 2019
PubMed
3) Yoshida A, Sekine S, Tsuta K, et al : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 36 : 993-999, 2012
PubMed
4) Charville GW, Varma S, Forgo E, et al : PAX7 expression in rhabdomyosarcoma, related soft tissue tumors, and small round blue cell neoplasms. Am J Surg Pathol 40 : 1305-1315, 2016
PubMed
5) Charville GW, Wang WL, Ingram DR, et al : EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol 30 : 1312-1320, 2017
PubMed
6) Toki S, Wakai S, Sekimizu M, et al : PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology 73 : 645-652, 2018
PubMed
7) Hornick JL, Fletcher CD : Pseudomyogenic hemangioendothelioma : a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 35 : 190-201, 2011
PubMed
8) Gangwal K, Sankar S, Hollenhorst PC, et al : Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A 105 : 10149-10154, 2008
 
9) Riggi N, Knoechel B, Gillespie SM, et al : EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26 : 668-681, 2014
PubMed
10) Pierron G, Tirode F, Lucchesi C, et al : A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 44 : 461-466, 2012
 
11) Kao YC, Owosho AA, Sung YS, et al : BCOR-CCNB3 fusion positive sarcomas : a clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas. Am J Surg Pathol 42 : 604-615, 2018
PubMed
12) Matsuyama A, Shiba E, Umekita Y, et al : Clinicopathologic diversity of undifferentiated sarcoma with BCOR-CCNB3 fusion : analysis of 11 cases with a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017
PubMed
13) Puls F, Niblett A, Marland G, et al : BCOR-CCNB3 (Ewing-like) sarcoma : a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol 38 : 1307-1318, 2014
PubMed
14) Yoshida A, Arai Y, Hama N, et al : Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology 76 : 509-520, 2020
PubMed
15) Wang GY, Thomas DG, Davis JL, et al : EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol 43 : 1112-1122, 2019
PubMed
16) Yoshida KI, Machado I, Motoi T, et al : NKX3-1 is a useful immunohistochemical marker of EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma. Am J Surg Pathol 44 : 719-728, 2020
PubMed
17) Cohen JN, Sabnis AJ, Krings G, et al : EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma : a case report and review of the literature. Hum Pathol 81 : 281-290, 2018
 
18) Diaz-Perez JA, Nielsen GP, Antonescu C, et al : EWSR1/FUS-NFATc2 rearranged round cell sarcoma : clinicopathological series of 4 cases and literature review. Hum Pathol 90 : 45-53, 2019
PubMed
19) Sadri N, Barroeta J, Pack SD, et al : Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion. Virchows Arch 465 : 233-239, 2014
PubMed
20) Szuhai K, IJszenga M, de Jong D, et al : The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 15 : 2259-2268, 2009
 
21) Szuhai K, M IJszenga Tanke HJ, et al : Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet 172 : 12-22, 2007
 
P.164 掲載の参考文献
1) Unni KK, Inwards CY : Dahlin's Bone Tumors (6th ed), Lippincott Williams & Wilkins, Philadelphia, 2010, pp184-190
 
2) Domson GF, Shahlaee A, Reith JD, et al : Infarct-associated bone sarcomas. Clin Orthop Relat Res 467 : 1820-1825, 2009
PubMed
3) Huvos AG, Woodard HQ, Heilweil M : Postradiation malignant fibrous histiocytoma of bone. A clinicopathologic study of 20 patients. Am J Surg Pathol 10 : 9-18, 1986
 
4) Martignetti JA, Gelb BD, Pierce H, et al : Malignant fibrous histiocytoma : inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. Genes Chromosomes Cancer 27 : 191-195, 2000
PubMed
5) Tarkkanen M, Larramendy ML, Bohling T, et al : Malignant fibrous histiocytoma of bone : analysis of genomic imbalances by comparative genomic hybridisation and CMYC expression by immunohistochemistry. Eur J Cancer 42 : 1172-1180, 2006
PubMed
6) Horvai AE, Roy R, Borys D, et al : Regulators of skeletal development : a cluster analysis of 206 bone tumors reveals diagnostically useful markers. Mod Pathol 25 : 1452-1461, 2012
PubMed
7) Conner JR, Hornick JL : SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology 63 : 36-49, 2013
PubMed
8) Yoshida A, Ushiku T, Motoi T, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012
PubMed
9) Bielack SS, Schroeders A, Fuchs N, et al : Malignant fibrous histiocytoma of bone : a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Acta Orthop Scand 70 : 353-360, 1999
 
10) Campanacci M : Bone and Soft Tissue Tumors (2nd ed), Springer, Wien, 1999, pp161-173
 
11) Abdelwahab IF, Kenan S, Hermann G, et al : Radiation-induced leiomyosarcoma. Skeletal Radiol 24 : 81-83, 1995
PubMed
12) Deyrup AT, Lee VK, Hill CE, et al : Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events : a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 30 : 75-82, 2006
 
13) Adelani MA, Schultenover SJ, Holt GE, et al : Primary leiomyosarcoma of extragnathic bone : clinicopathologic features and reevaluation of prognosis. Arch Pathol Lab Med 133 : 1448-1456, 2009
PubMed
P.169 掲載の参考文献
1) de Saint-Aubain Somerhausen N, van de Rijn M : Tenosynovial giant cell tumour. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone Tumours" (5 th ed), IARC Press, Lyon, 2020, pp133-136
 
2) Goldblum JR, Folpe AL, Weiss SW : Enzinger & Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philadelphia, 2020, pp863-884
 
3) Vigorita VJ : Orthopaedic Pathology (2nd ed), Lippincott Williams & Wilkins, Philadelphia, 2008, pp610-620
 
4) 江原茂 : 骨・関節のX線診断, 金原出版, 1995, pp235-236
 
5) Osanai T, Suzuki H, Hiraga H, et al : Extra-articular diffuse-type tenosynovial giant cell tumor with benign histological features resulting in fatal pulmonary metastases : A case report. J Orthop Surg 25 : 2309499017690323, 2017
 
6) Liegl-Atzwanger B, Hornick JL : Giant cell-rich tumours. in Hornick JL (ed) : "Practical Soft Tissue Pathology : A Diagnostic Approach", Elsevier Saunders, Philadelphia, 2013, pp279-292
 
7) Oda Y, Izumi T, Harimaya K, et al : Pigmented villonodular synovitis with chondroid metaplasia, resembling chondroblastoma of the bone : A report of three cases. Mod Pathol 20 : 545-551, 2007
 
8) Fisher M, Biddinger P, Folpe AL, et al : Chondroid tenosynovial giant cell tumor of the temporal bone. Otol Neurotol 34 : e49-e50, 2013
PubMed
9) Boland JM, Folpe AL, Hornick JL, et al : Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types : diagnostic and histogenetic implications. Am J Surg Pathol 33 : 1225-1229, 2009
PubMed
10) Grogg KL, Lae ME, Kurtin PJ, et al : Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms : Report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors. Am J Surg Pathol 28 : 988-998, 2004
 
P.173 掲載の参考文献
1) Flanagan AM, Bloem JL, Cates JMM. Synovial chondromatosis. in WHO classification of tumours editorial board (ed) : "WHO Classification of Tumours, Soft Tissue and Bone tumours" (5 th ed), IARC Press, Lyon, pp368-369, 2020
 
2) Davis RI, Hamilton A, Biggart JD : Primary synovial chondromatosis : a clinicopathologic review and assessment of malignant potential. Hum Pathol 29 : 683-688, 1998
PubMed
3) Fetsch JF, Vinh TN, Remotti F, et al : Tenosynovial (extraarticular) chondromatosis : an analysis of 37 cases of an underrecognized clinicopathologic entity with a strong predilection for the hands and feet and a high local recurrence rate. Am J Surg Pathol 27 : 1260-1268, 2003
 
4) Murphey MD, Vidal JA, Fanburg-Smith JC, et al : Imaging of synovial chondromatosis with radiologic-pathologic correlation. Radiographics 27 : 1465-1488, 2007
PubMed
5) 石田剛, 今村哲夫 : 非腫瘍性骨関節疾患の病理, 文光堂, 2003, pp54-61
 
6) Bertoni F, Unni KK, Beabout JW, et al : Chondrosarcomas of the synovium. Cancer 67 : 155-162, 1991
PubMed
7) Totoki Y, Yoshida A, Hosoda F, et al : Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res 24 : 1411-1420, 2014
PubMed
8) Amary F, Perez-Casanova L, Ye H, et al : Synovial chondromatosis and soft tissue chondroma : extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Mod Pathol 32 : 1762-1771, 2019
PubMed
9) Amary MF, Bacsi K, Maggiani F, et al : IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224 : 334-343, 2011
 
10) Damato S, Alorjani M, Bonar F, et al : IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology 60 : 363-365, 2012
 
11) de Sa D, Horner NS, MacDonald A, et al : Arthroscopic surgery for synovial chondromatosis of the hip : a systematic review of rates and predisposing factors for recurrence. Arthroscopy 30 : 1499-1504.e2, 2014
 
12) Sah AP, Geller DS, Mankin HJ, et al : Malignant transformation of synovial chondromatosis of the shoulder to chondrosarcoma. A case report. J Bone Joint Surg Am 89 : 1321-1328, 2007
PubMed
13) O'Connell JX : Pathology of the synovium. Am J Clin Pathol 114 : 773-784, 2000
PubMed
P.176 掲載の参考文献
1) Amarjit KS, Budhiraja S, Chandramouleeswari K, et al : Knee locking in osteoarthritis due to synovial lipoma : a case report. J Clin Diagn Res 7 : 1708-1709, 2013
 
2) Sanamandra SK, Ong KO : Lipoma arborescens. Singapore Med J 55 : 5-11, 2014
PubMed
3) Bejia I, Younes M, Moussa A, et al : Lipoma arborescens affecting multiple joints. Skeletal Radiol 34 : 536-538, 2005
PubMed
4) Kim S, Lee GY, Ha YC : An intra-articular synovial lipoma of the hip, possibly causing osteoarthritis : a case report and review of the literature. Skeletal Radiol 47 : 717-721, 2018
 
5) Natera L, Gelber PE, Erquicia JI, et al : Primary lipoma arborescens of the knee may involve the development of early osteoarthritis if prompt synovectomy is not performed. J Orthop Traumatol 16 : 47-53, 2015
 

第3部 鑑別ポイント

P.187 掲載の参考文献
1) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp55-118
 
2) Yoshida A, Ushiku T, Motoi T, et al : Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 23 : 1279-1288, 2010
PubMed
3) Yalcinkaya U, Doganavsargil B, Sezak M, et al : Clinical and morphological characteristics of osteoid osteoma and osteoblastoma : a retrospective single-center analysis of 204 patients. Ann Diagn Pathol 18 : 319-325, 2014
PubMed
4) Dor fman HD, Weiss SW : Borderline osteoblastic tumors : problems in the differential diagnosis of aggressive osteoblastoma and low-grade osteosarcoma. Semin Diagn Pathol 1 : 215-234, 1984
 
5) 石田剛, 今村哲夫 : 非腫瘍性骨関節疾患の病理, 文光堂, 2003, pp177-201
 
6) Spjut HJ, Dorfman HD : Florid reactive periostitis of the tubular bones of the hands and feet. A benign lesion which may simulate osteosarcoma. Am J Surg Pathol 5 : 423-433, 1981
 
7) Tabareau-Delalande F, Collin C, Gomez-Brouchet A, et al : Diagnostic value of investigating GNAS mutations in fibro-osseous lesions : a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod Pathol 26 : 911-921, 2013
PubMed
8) Nora FE, Dahlin DC, Beabout JW : Bizarre parosteal osteochondromatous proliferations of the hands and feet. Am J Surg Pathol 7 : 245-250, 1983
PubMed
9) Nilsson M, Domanski HA, Mertens F, et al : Molecular cytogenetic characterization of recurrent translocation breakpoints in bizarre parosteal osteochondromatous proliferation (Nora's lesion). Hum Pathol 35 : 1063-1069, 2004
 
P.193 掲載の参考文献
1) Kerr DA, Lopez HU, Deshpande V, et al : Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol 37 : 787-795, 2013
PubMed
2) Pansuriya TC, van Eijk R, d'Adamo P, et al : Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43 : 1256-1261, 2011
PubMed
3) Papke DJ, Hung YP, Schaefer IM, et al : Clinicopathologic characterization of malignant chondroblastoma : a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma. Mod Pathol 33 : 2295-2306, 2020
PubMed
4) Amary MF, Berisha F, Mozela R, et al : The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology 69 : 121-127, 2016
 
5) Bianco P, Riminucci M, Majolagbe A, et al : Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 15 : 120-128, 2000
PubMed
P.203 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2020
 
2) Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds) : World Health Organization Classification of Tumours of Soft Tissue and Bone (4th ed), IARC Press, Lyon, 2013
 
3) Agaram NP, LeLoarer FV, Zhang L, et al : USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol 45 : 1147-1152, 2014
 
4) Amary F, Berisha F, Ye H, et al : H3F3A (histone 3.3) G34W immunohistochemistry : a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 41 : 1059-1068, 2017
PubMed
5) Bai YQ, Yang TT, Zhang HZ : The study of the value of H3F3A G34W immunohistochemical staining in the diagnosis of giant cell tumor of bone. Zhonghua Bing Li Xue Za Zhi 48 : 531-536, 2019
 
6) Oliveira AM, Perez-Atayde AR, Inwards CY, et al : USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 165 : 1773-1780, 2004
PubMed
7) Behjati S, Tarpey PS, Presneau N, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013
PubMed
8) Lu C, Ramirez D, Hwang S, et al : Histone H3K36M mutation and trimethylation patterns in chondroblastoma. Histopathology 74 : 291-299, 2019
PubMed
9) Schaefer IM, Fletcher JA, Nielsen GP, et al : Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol 126 : 552-566, 2018
PubMed
10) Nagata S, Nishimura H, Uchida M, et al : Giant cell-rich osteosarcoma of the distal femur : radiographic and magnetic resonance imaging findings. Radiat Med 24 : 228-232, 2006
PubMed
11) Romeo S, Bovee JVMG, Kroon HM, et al : Malignant fibrous histiocytoma and fibrosarcoma of bone : a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch 461 : 561-570, 2012
 
P.212 掲載の参考文献
1) Shibuya R, Matsuyama A, Nakamoto M, et al : The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Arch 465 : 599-605, 2014
PubMed
2) Yoshida A, Sekine S, Tsuta K, et al : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 36 : 993-999, 2012
PubMed
3) Toki S, Wakai S, Sekimizu M, et al : PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology 73 : 645-652, 2018
PubMed
4) Kawamura-Saito M, Yamazaki Y, Kaneko K, et al : Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t (4 ; 19) (q35 ; q13) translocation. Hum Mol Genet 15 : 2125-2137, 2006
 
5) Specht K, Sung YS, Zhang L, et al : Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas : further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 53 : 622-633, 2014
PubMed
6) Sugita S, Arai Y, Tonooka A, et al : A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma : a genetically distinct variant of Ewing-like sarcoma. Am J Surg Pathol 38 : 1571-1576, 2014
PubMed
7) Yoshida A, Goto K, Kodaira M, et al : CIC-rearranged sarcomas : a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol 40 : 313-323, 2016
PubMed
8) Le Guellec S, Velasco V, Perot G, et al : ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas : a study of 127 cases including mimicking lesions. Mod Pathol 29 : 1523-1531, 2016
 
9) Pierron G, Tirode F, Lucchesi C, et al : A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 44 : 461-466, 2012
 
10) Shibayama T, Okamoto T, Nakashima Y, et al : Screening of BCOR-CCNB3 sarcoma using immunohistochemistry for CCNB3 : a clinicopathological report of three pediatric cases. Pathol Int 65 : 410-414, 2015
PubMed
11) Matsuyama A, Shiba E, Umekita Y, et al : Clinicopathologic diversity of undifferentiated sarcoma with BCOR-CCNB3 fusion : analysis of 11 cases with a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017
PubMed
12) Yoshida KI, Machado I, Motoi T, et al : NKX3-1 is a useful immunohistochemical marker of EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma. Am J Surg Pathol 44 : 719-728, 2020
PubMed
13) Nakajima H, Sim FH, Bond JR, et al : Small cell osteosarcoma of bone. Review of 72 cases. Cancer 79 : 2095-2106, 1997
PubMed
14) Righi A, Gambarotti M, Longo S, et al : Small cell osteosarcoma : clinicopathologic, immunohistochemical, and molecular analysis of 36 cases. Am J Surg Pathol 39 : 691-699, 2015
PubMed
15) Sim FH, Unni KK, Beabout JW, et al : Osteosarcoma with small cells simulating Ewing's tumor. J Bone Joint Surg Am 61 : 207-215, 1979
PubMed
16) Machado I, Alberghini M, Giner F, et al : Histopathological characterization of small cell osteosarcoma with immunohistochemistry and molecular genetic support. A study of 10 cases. Histopathology 57 : 162-167, 2010
PubMed
17) Debelenko LV, McGregor LM, Shivakumar BR, et al : A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma. Genes Chromosomes Cancer 50 : 1054-1062, 2011
 
18) Wojcik JB, Bellizzi AM, Dal Cin P, et al : Primary sclerosing epithelioid fibrosarcoma of bone : analysis of a series. Am J Surg Pathol 38 : 1538-1544, 2014
PubMed
19) Maruyama D, Watanabe T, Beppu Y, et al : Primary bone lymphoma : a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 37 : 216-223, 2007
 
20) Nagasaka T, Nakamura S, Medeiros LJ, et al : Anaplastic large cell lymphomas presented as bone lesions : a clinicopathologic study of six cases and review of the literature. Mod Pathol 13 : 1143-1149, 2000
PubMed
21) Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al : Precursor B-lymphoblastic lymphoma presenting as a solitary bone tumor and mimicking Ewing's sarcoma : a report of four cases and review of the literature. Am J Surg Pathol 22 : 795-804, 1998
PubMed
22) Lin O, Filippa DA, Teruya-Feldstein J : Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL) : a potential diagnostic pitfall. Appl Immunohistochem Mol Morphol 17 : 409-412, 2009
PubMed
23) Meis JM, Butler JJ, Osborne BM, et al : Granulocytic sarcoma in nonleukemic patients. Cancer 58 : 2697-2709, 1986
PubMed
24) Nakashima Y, Unni KK, Shives TC, et al : Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 57 : 2444-2453, 1986
 
25) Wehrli BM, Huang W, De Crombrugghe B, et al : Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 34 : 263-269, 2003
PubMed
26) Bishop JA, Alaggio R, Zhang L, et al : Adamantinoma-like Ewing family tumors of the head and neck : a pitfall in the differential diagnosis of basaloid and myoepithelial carcinomas. Am J Surg Pathol 39 : 1267-1274, 2015
PubMed
P.220 掲載の参考文献
1) Kurzawa P, Kattapuram S, Hornicek FJ, et al : Primary myoepithelioma of bone : a report of 8 cases. Am J Surg Pathol 37 : 960-968, 2013
 
2) Vujovic S, Henderson S, Presneau N, et al : Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209 : 157-165, 2006
PubMed
3) Miettinen M, Wang Z, Lasota J, et al : Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas : an immunohistochemical study of 5229 cases. Am J Surg Pathol 39 : 1305-1312, 2015
PubMed
4) Shibuya R, Matsuyama A, Shiba E, et al : CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 67 : 827-835, 2015
PubMed
5) Doyle LA, Fletcher CD, Hornick JL : Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am J Surg Pathol 40 : 94-102, 2016
PubMed
6) Yoshida A, Sekine S, Tsuta K, et al : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 36 : 993-999, 2012
PubMed
7) Shibuya R, Matsuyama A, Nakamoto M, et al : The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Arch 465 : 599-605, 2014
PubMed
8) Toki S, Wakai S, Sekimizu M, et al : PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology 73 : 645-652, 2018
PubMed
9) Yoshida KI, Machado I, Motoi T, et al : NKX3-1 is a useful immunohistochemical marker of EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma. Am J Surg Pathol 44 : 719-728, 2020
PubMed

第4部 臨床との連携

P.225 掲載の参考文献
1) 日本整形外科学会, 日本病理学会編 : 整形外科・病理 悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015, pp42-51
 
2) Malawer MM, Bickels J, Meller I, et al : Cryosurgery in the treatment of giant cell tumor. A long-term follow up study. Clin Orthop Relat Res (359) : 176-188, 1999
PubMed
3) Lin WH, Lan TY, Chen CY, et al : Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop Relat Res 469 : 3200-3208, 2011
PubMed
4) Kawaguchi N, Matumoto S, Manabe J : New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma : analysed on the basis of 457 surgical cases. J Cancer Res Clin Oncol 121 : 555-563, 1995
 
5) Weber MA, Sprengel SD, Omlor GW, et al : Clinical long-term outcome, technical success, and cost analysis of radiofrequency ablation for the treatment of osteoblastomas and spinal osteoid osteomas in comparison to open surgical resection. Skeletal Radiol 44 : 981-993, 2015
PubMed
6) Gaston CL, Bhumbra R, Watanuki M, et al : Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br 93 : 1665-1669, 2011
 
7) Manabe J, Ahmed AR, Kawaguchi N, et al : Pasteurized autologous bone graft in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res (419) : 258-266, 2004
 
8) Sugiura H, Takahashi M, Nakanishi K, et al : Pasteurized intercalary autogenous bone graft combined with vascularized fibula. Clin Orthop Relat Res 456 : 196-202, 2007
PubMed
9) Tsuchiya H, Wan SL, Sakayama K, et al : Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87 : 218-225, 2005
PubMed
P.231 掲載の参考文献
1) Madewell JE, Ragsdale BD, Sweet DE : Radiologic and pathologic analysis of solitary bone lesions. Part I : internal margins. Radiol Clin North Am 19 : 715-748, 1981
 
2) Ragsdale BD, Madewell JE, Sweet DE : Radiologic and pathologic analysis of solitary bone lesions. Part II : periosteal reactions. Radiol Clin North Am 19 : 749-783, 1981
 
3) Sweet DE, Madewell JE, Ragsdale BD : Radiologic and pathologic analysis of solitary bone lesions. Part III : matrix patterns. Radiol Clin North Am 19 : 785-814, 1981
 
4) Mueller DL, Grant RM, Riding MD, et al : Cortical saucerization : an unusual imaging finding of Ewing sarcoma. AJR Am J Roentgenol 163 : 401-403, 1994
PubMed
5) Expert Panel on Musculoskeletal Imaging, Bestic JM, Wessell DE, et al : ACR Appropriateness CriteriaR. Primary Bone Tumors. J Am Coll Radiol 17 : s226-s238, 2020
 
6) 日本医学放射線学会編 : 画像診断ガイドライン 2016年版, 金原出版, 2016
 
7) Aoki J, Tanikawa H, Ishii K, et al : MR findings indicative of hemosiderin in giant-cell tumor of bone : frequency, cause, and diagnostic significance. AJR Am J Roentgenol 166 : 145-148, 1996
PubMed
8) Reddick WE, Wang S, Xiong X, et al : Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 91 : 2230-2237, 2001
PubMed
9) Aoki T, Yamashita Y, Oki H, et al : Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) of the wrist and finger at 3T : comparison with chemical shift selective fat suppression images. J Magn Reson Imaging 37 : 733-738, 2013
PubMed
10) Nakai T, Okuyama C, Kubota T, et al : Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32 : 1253-1258, 2005
 
11) Bastiaannet E, Groen H, Jager PL, et al : The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas ; a systematic review and meta-analysis. Cancer Treat Rev 30 : 83-101, 2004
PubMed
12) Feldman F, van Heertum R, Manos C : 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32 : 201-208, 2003
PubMed
P.236 掲載の参考文献
1) Brierley JD, Gospodarowicz MK, Wittekind C (ed) : TNM 悪性腫瘍の分類 第8版 日本語版, UICC日本委員会TNM委員会訳, 金原出版, 2017
 
2) 日本整形外科学会, 日本病理学会編 : 整形外科・病理 悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015, p60
 
3) Iwamoto Y, Tanaka K, Isu K, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009
PubMed
4) Marina NM, Smeland S, Bielack SS, et al : Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial. Lancet Oncol 17 : 1396-1408, 2016
PubMed
5) Iwamoto Y, Tanaka K : The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol 42 : 467-470, 2012
 
6) Womer RB, West DC, Krailo MD, et al : Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma : a report from the Children's Oncology Group. J Clin Oncol 30 : 4148-4154, 2012
 
7) Kawaguchi S, Sun T, Lin PP, et al : Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin Orthop Relat Res 472 : 983-989, 2014
 
8) Italiano A, Mir O, Cioffi A, et al : Advanced chondrosarcomas : role of chemotherapy and survival. Ann Oncol 24 : 2916-2922, 2013
PubMed
9) Dickey ID, Rose PS, Fuchs B, et al : Dedifferentiated chondrosarcoma : the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 86 : 2412-2418, 2004
PubMed
10) Cesari M, Bertoni F, Bacchini P, et al : Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 93 : 423-427, 2007
 
11) Ferrari S, Bielack SS, Smeland S, et al : EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40 : Outcome in primary high-grade osteosarcoma. Tumori 104 : 30-36, 2018
 
12) Imai R, Kamada T, Araki N, et al : Carbon ion radiation therapy for unresectable sacral chordoma : an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95 : 322-327, 2016
PubMed
P.241 掲載の参考文献
1) Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, et al : Molecular pathology of bone tumors. J Mol Diagn 21 : 171-182, 2019
PubMed
2) Horvai AE, Roy R, Borys D, et al : Regulators of skeletal development : a cluster analysis of 206 bone tumors reveals diagnostically useful markers. Mod Pathol 25 : 1452-1461, 2012
PubMed
3) Conner JR, Hornick JL : SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology 63 : 36-49, 2013
PubMed
4) Hosono A, Yamaguchi U, Makimoto A, et al : Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma. J Clin Pathol 60 : 410-414, 2007
PubMed
5) Wan Y, Zhao W, Jiang Y, et al : β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. Hum Pathol 45 : 1459-1465, 2014
 
6) Fittall MW, Mifsud W, Pillary N, et al : Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9 : 2150, 2018
 
7) Yoshida A, Ushiku T, Motoi T, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012
PubMed
8) Konishi E, Nakashima Y, Iwasa Y, et al : Immunohistochemical analysis for Sox9 reveals the cartilaginous character of chondroblastoma and chondromyxoid fibroma of the bone. Hum Pathol 41 : 208-213, 2010
PubMed
9) Szuhai K, Cleton-Jansen AM, Hogendoorn PCW, et al : Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 205 : 193-204, 2012
 
10) Shibuya R, Matsuyama A, Nakamoto M, et al : The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Arch 465 : 599-605, 2014
PubMed
11) Charville GW, Wang WL, Ingram DR, et al : EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol 30 : 1312-1320, 2017
PubMed
12) Peters TL, Kumar V, Polikepahad S, et al : BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. Mod Pathol 28 : 575-586, 2015
PubMed
13) Behjati S, Tarpey PS, Presneau N, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013
PubMed
14) Oliveira AM, Chou MM : USP6-induced neoplasms : the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol 45 : 1-11, 2014
PubMed
15) Roden AC, Hu X, Kip S, et al : BRAF V600E expression in Langerhans cell histiocytosis : clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38 : 548-551, 2014
 
16) Shibuya R, Matsuyama A, Shiba E, et al : CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 67 : 827-835, 2015
PubMed
17) Antonescu CR, Le Loarer F, Mosquera JM, et al : Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52 : 775-784, 2013
PubMed
18) Athanasou NA, Quinn J, Heryet A, et al : Effect of decalcification agents on immunoreactivity of cellular antigens. J Clin Pathol 40 : 874-878, 1987
PubMed
19) Bussolati G, Leonardo E : Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61 : 1184-1192, 2008
PubMed
P.250 掲載の参考文献
1) 日本整形外科学会, 日本病理学会編 : 整形外科・病理 悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015
 
2) 落合淳志 : 癌の治療効果と病理組織診断, 各種治療後の病理組織診断 (総論). 病理と臨床 26 : 440-446, 2008
 
3) Ayala AG, Raymond AK, Jaffe N : The pathologist's role in the diagnosis and treatment of osteosarcoma in children. Hum Pathol 15 : 258-266, 1984
 
4) Picci P, Bacci G, Campanaci M, et al : Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56 : 1515-1521, 1985
 
5) 平賀博明, 野島孝之, 小田義直, 他 : 日本臨床腫瘍研究グループ骨軟部腫瘍グループ JCOG0905 資料, 2008
 
6) 蛭田啓之, 町並陸生, 神田浩明, 他 : 骨肉腫の術前化学療法組織学的効果判断と問題点. 日本整形外科學會雑誌 84 : 1120-1125, 2010
 
7) 日本整形外科学会骨・軟部腫瘍委員会編 : 骨・軟部肉腫切除縁評価法, 金原出版, 1989
 
8) Kawaguchi N, Matsumoto S, Manabe J : New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma, analysed on the basis of 457 surgical cases. J Cancer Res Clin Oncol 121 : 555-563, 1995
 
9) Kawaguchi N, Ahmed AR, Matsumoto S, et al : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res (419) : 165-172, 2004
 
10) 阿江啓介, 松本誠一, 下地尚, 他 : 切除縁評価法の改正にむけて-バリア概念の検証. 日本整形外科學會雑誌 88 : 567-574, 2014
 
11) Matsumoto S (ed) : Modern Surgical Challenges for Musculoskeletal Sarcoma, Proceeding from 26th Annual Meeting of Surgical Treatment for Musculoskeletal Sarcoma, Vol 19, 2017
 
12) 松本誠一, 阿江啓介 : サルコーマの疫学と治療法の原則. 臨床外科 80 : 301-307, 2018
 
13) 阿江啓介, 松本誠一 : 肉腫外科治療の最前線 : 切除縁-ユニークな切除縁評価法と, 根拠に基づく安全な手術計画. 医学のあゆみ 254 : 285-290, 2015
Medical*Online
14) 阿江啓介, 松本誠一 : 新しい切除縁評価とその概念. Bone Joint Nerve 7 : 459-468, 2017
Medical*Online
P.255 掲載の参考文献
1) 三上芳喜 : 病理組織・細胞診断報告書の読み方. 笹野公伸, 森谷卓也, 真鍋俊明編 : 臨床医・初期研修医のための病理検査室利用ガイド 病理検査の依頼からCPCレポートの作成まで, 文光堂, 2004, pp83-111
 
2) 日本整形外科学会, 日本病理学会編 : 整形外科・病理 悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015
 
3) Laster S : Manual of Surgical Pathology, Churchill Livingstone, Philadelphia, 2001, pp116-128
 
4) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours, Soft Tissue and Bone (5th ed), IARC Press, Lyon, 2020, pp340-344
 
5) Evans HL, Ayala AG, Romsdahl MM : Prognostic factors in chondrosarcoma of bone : a clinicopathologic analysis with emphasis on histologic grading. Cancer 40 : 818-831, 1977
 
6) Edge SB, Byrd DR, Compton CC, et al (eds) : AJCC Cancer Staging Manual (7th ed), Springer, New York, 2010
 
7) Brierly JD, Gospondarowicz MK, Wittekind C (eds) : TNM Classification of Malignant Tumours (8th ed), Wiley Blackwell, Oxford and Hoboken, 2017
 
8) UICC : Publications and Resources, updated 4 August 2020, https://www.uicc.org/resources/tnm/publicationsresources
 

書評

最近チェックした商品履歴

Loading...